Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
The update follows Mizuho's initiation of coverage on the stock on December 18 with an Outperform rating and a share price target of $53, where it cited potential in the company's pipeline of anti-monoclonal antibodies to treat inflammatory bowel disease (IBD). In November, the biotech company shared positive findings from its Phase 1 human trial of SPY003, an extended half-life antibody to cure IBD. The tests performed on 59 participants with varying doses showed that the drug was well received at all levels, with a half-life of nearly 85 days, strengthening the case for quarterly or two annual maintenance doses. According to TipRanks, in a research note to investors, Mizuho praised the company's expertise in testing new combinations for treatments, which could help drive growth in the future. The firm projects Spyre Therapeutics, Inc. (NASDAQ:SYRE)'s global sales to reach $1.7 billion by 2035. Wall Street analysts have a bullish outlook on the stock with a consensus Strong Bu
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.MarketBeat
- Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2GlobeNewswire
- Spyre Therapeutics' CEO Sells 15,000 Shares [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics Announces Grants of Inducement AwardsGlobeNewswire
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- 1/13/26 - Form 4
- SYRE's page on the SEC website